Molecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkey

Basit Öğe Kaydı
dc.authoridaktas, elif/0000-0003-3087-5425
dc.authoridDURMAZ, RIZA/0000-0001-6561-778X
dc.authorwosidDURMAZ, Rıza/HJH-4918-2023
dc.authorwosidaktas, elif/ACL-9792-2022
dc.contributor.authorAktas, E
dc.contributor.authorDurmaz, R
dc.contributor.authorYang, D
dc.contributor.authorYang, ZH
dc.date.accessioned2024-08-04T20:14:45Z
dc.date.available2024-08-04T20:14:45Z
dc.date.issued2005
dc.departmentİnönü Üniversitesien_US
dc.description.abstractMolecular characterization of drug resistance of Mycobacterium tuberculosis strains of different origins can generate information useful for developing molecular methods that are widely applicable for rapid drug resistance detection. Using DNA sequencing and allele-specific polymerase chain reaction (AS-PCR), we investigated genetic mutations associated with isoniazid (INH) and rifampin (RIF) resistance among 29 drug-resistant clinical isolates of M. tuberculosis collected from Malatya, Turkey, including 19 multi-drug-resistant (MDR) isolates. Point mutations were detected at codons 531, 516, 526, and 513 of the RNA polymerase beta-subunit gene (rpoB) in 10 (47.6%), five (23.8%), three (14.3%), and three (14.3%) of the 21 RIF-resistant isolates, respectively. Of the five isolates having mutations in codon 516, three also had mutations at codon 527; one had a concurrent mutation at codon 572. Mutations at codon 315 of the catalase-peroxidase-encoding gene (katG) were found in 17 (63.0%) of the 27 INH-resistant isolates. Interestingly, the katG codon 315 mutation was observed at a much higher frequency in MDR isolates than in INH-mono-resistant isolates (similar to 79% vs. 25%). This study provided the first molecular characterization of INH and RIF resistance of M. tuberculosis clinical isolates from Eastern Turkey, and extended our knowledge of molecular basis of M. tuberculosis drug resistance.en_US
dc.identifier.doi10.1089/mdr.2005.11.94
dc.identifier.endpage99en_US
dc.identifier.issn1076-6294
dc.identifier.issn1931-8448
dc.identifier.issue2en_US
dc.identifier.pmid15910221en_US
dc.identifier.scopus2-s2.0-18944394017en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage94en_US
dc.identifier.urihttps://doi.org/10.1089/mdr.2005.11.94
dc.identifier.urihttps://hdl.handle.net/11616/93947
dc.identifier.volume11en_US
dc.identifier.wosWOS:000229308400002en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherMary Ann Liebert, Incen_US
dc.relation.ispartofMicrobial Drug Resistanceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectRifamycin Cross-Resistanceen_US
dc.subjectDrug-Resistanceen_US
dc.subjectRpob Mutationsen_US
dc.subjectEpidemiologyen_US
dc.subjectStrainsen_US
dc.subjectCodon-315en_US
dc.subjectAllelesen_US
dc.subjectKatgen_US
dc.titleMolecular characterization of isoniazid and rifampin resistance of Mycobacterium tuberculosis clinical isolates from Malatya, Turkeyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu